A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia

This study is testing a new CAR-T cell therapy targeting a protein called GPRC5D for people with multiple myeloma or plasma cell leukemia that has returned or stopped responding to treatment. CAR-T therapy involves engineering your own immune cells in the lab to recognize and attack cancer cells. **You may be eligible if...** - You are 18–75 years old - You have had at least 3 prior lines of therapy for multiple myeloma or plasma cell leukemia, including a proteasome inhibitor and an immunomodulatory drug - Your myeloma cells test positive for the GPRC5D protein - You have measurable disease (detectable cancer markers in blood, urine, or bone marrow) - You are in reasonable physical condition (ECOG score of 0–2) - Your organ function meets the required levels **You may NOT be eligible if...** - You have had a prior organ transplant - You have active hepatitis B, hepatitis C, HIV, or cytomegalovirus (CMV) infection - You have uncontrolled high blood pressure or serious heart disease - You have another active cancer (beyond the myeloma being treated) - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.